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bhe evidence for heritability of myocardial infarction
MI) is striking, with a positive family history being one
f the most important risk factors for this complex trait
1). The term “complex trait” implies both gene-
nvironment and gene-gene interaction, along with the
omplexity of inheritance distinct from “simple” Mende-
ian traits such as those with an autosomal-dominant,
utosomal recessive, X-linked, or mitochondrial basis (2).
hereas a complex trait is common and probabilistic in
henotypic manifestation, a Mendelian trait is considered
o be rare and deterministic (2). Willett (3) has pointed
ut that more than 80% of coronary heart disease may
e accountable by lifestyle issues, such as weight, diet,
xercise, and control of risk factors such as blood pressure
nd smoking. Yet, the influence of genetics is also quite
mportant, and recent work in this field has led to
etermining key genes associated with increased risk of
usceptibility for acute MI. This paper will review the
apid and substantive progress that has been made in
dentifying genes that influence susceptibility for MI.
ENETICS OF ATHEROSCLEROSIS
ND MI ARE DIFFERENT
therosclerotic coronary artery disease (CAD) is nearly
ervasive, and one can conservatively project well over 50
illion American adults have some atheromatous disease.
his is based on autopsy specimens of young and old
dults, along with assessment by intravascular ultrasound
n individuals without symptoms of angina or ischemic
eart disease (4,5). Yet despite this very large universe of
atients with atherosclerotic involvement of their coro-
ary arteries, only a small fraction will ever develop an
I—in the U.S. this is estimated to be approximately
ne million people per year (6). In virtually all of our
enetic studies to date, we have noted that the heritability
f MI is much more impressive than CAD (1,7). The
ikely explanation for this observation is that only a
imited number of individuals have particular susceptibil-
ty to have active arterial inflammation culminating in
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ccepted June 20, 2005.laque rupture, erosion, or fissuring to induce an acute
oronary syndrome. Recently, Fischer et al. (8) studied
01 families with MI by comparing angiograms among
iblings. Remarkable concordance among 882 siblings
as noted for the location of the lesions in the coronary
ree, with statistical significance for ostial, left main stem,
nd proximal locations. Not only having underlying
oronary disease, but also in the same location in the
oronary tree, further emphasizes the importance of the
enetic basis of this disease in families with MI. In order
o understand the actual genes responsible for MI sus-
eptibility, direct assessment of the genome of individuals
s requisite.
HE HUMAN GENOME
he human genome is much simpler than originally
rojected when the draft sequence was announced in June
000 (9). There are only approximately 26,000 genes,
iving rise to about 100,000 proteins (more proteins than
enes because of alternative splicing). Remarkably, indi-
idual heterogeneity of the 3.1 billion base pairs (bp)
rom person to person is based upon only 0.1%, or 3
illion bps at play of the total 10 million single nucleo-
ide polymorphisms (SNP). In Figure 1, a simplified
raphic depiction of an SNP, haplotype, and microsatel-
ite is provided. An SNP is simply a bp in which a coding
etter of the four nucleotides (A, G, T, C) can be
ubstituted. A haplotype is a collection of SNPs, often
xtending over thousands of bases. A microsatellite refers
o a tandem repeat sequence much longer than that
llustrated, and useful not only as a marker in the genome
ut also, at times, responsible for harboring disease-
ausing genes. These terms are important to understand
he progress that is being made in high throughput
enotyping, genomewide scans, and whole genome SNP
apping.
In Figure 2, the jumps in the field of complex trait
etermination are summarized in a ladder-type diagram.
tarting at the bottom with case-control association
tudies involving a single SNP, we have moved to
tudying hundreds or thousands of SNPs simultaneously
s an outgrowth of high throughput genotyping. Beyond
hese methods, genome-wide scanning using microsatel-
ites is a classic approach to be described more thoroughly
elow. Very dense SNP mapping, involving millions of
NPs, may ultimately take its place. If it can be provided
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October 18, 2005:1456–65 Genomics of MIithout prohibitive expense, complete re-sequencing of
he individual genome could indeed lie ahead in the
uture. As one goes up the ladder, there is with each
echnique progressively less bias, more expense, and more
nformation. Advances in technology of performing
enotyping are reflected by the cost moving from $1.00
er bp analysis to a projection of a hundredth of a cent in
oming years (2).
ROGRESS IN SNPS
he most extensively studied polymorphism in cardio-
ascular medicine is apolipoprotein (apo) E (10). In this
ene, amino acid substitutions at residues 112 and 158
re responsible for three variants: apoE2 (cysteine, cys-
eine), apoE3 (cysteine, arginine), and apoE4 (arginine,
rginine), respectively. A meta-analysis of 48 studies
nvolving over 15,000 cases and 32,000 controls has
hown the odds ratio for CAD is at least 1.4 for apoE4
arriers compared with E3 controls. This same polymor-
hism, present in 20% of the population, has been
ssociated with a heightened risk of Alzheimer’s disease
nd reduced lifespan (11). Its replication for association
ith CAD across tens of population cohorts is exemplary,
ut the functional genomics of precisely how the apoE4
olymorphism sets up susceptibility for MI and CAD is
ncompletely understood. Most patients with this poly-
orphism have high low-density lipoprotein cholesterol
evels, and exquisite sensitivity to statins for clinical
utcome benefits has been noted (12).
The work in apoE4 is largely derived from single-allele
ase-association studies. In recent years, high throughput
NP studies have become more commonplace. The first
igh throughput study in MI demonstrated the impor-
ance of the thrombospondin (TSP) family of matricel-
ular proteins for association with premature MI in over
00 affected families (7). Three different TSP SNPs—in
Abbreviations and Acronyms
apo  apolipoprotein
CAD  coronary artery disease
FLAP  5-lipooxygenase activating protein
LOD  logarithm of the odds ratio
LTA  lymphotoxin alpha
MEF2A  myocyte-enhancing factor 2A
MI  myocardial infarction
SNP  single nucleotide polymorphism
TSP  thrombospondint
igure 1. Single nucleotide polymorphisms (SNP), haplotypes (HAP), and
icrosatellites (MS).ifferent TSP genes 1, 2, and 4 —prevailed in association
ith premature MI among over 100 candidate genes that
ere assessed (7,13). Of note, the TSP-4 SNP is a
ommon SNP with the minor allele present in over 30%
f individuals and conferring a near two-fold risk of MI.
his leads to a substitution of proline for alanine in the
SP-4 protein, and with that a marked increase in
alcium binding for this key type II repeat binding site of
he TSP-4 protein. This “gain-of-function” mutation is
orrelated with extensive proinflammatory effects includ-
ng a striking reduction in endothelial proliferation or
nability to repair from endothelial injury (Fig. 3), and
nhanced neutrophil function (14). The association of
his TSP-4 SNP has been independently replicated in
ther case-control studies (15–17). A number of other
NPs have been similarly validated for MI for CAD in at
east three independent studies, with functional genomic
ork, as provided in Table 1 (7,13,18 –21).
Ozaki et al. (19) in Japan have taken the high-
hroughput SNP study field to a new threshold. By
nalyzing more than 65,000 SNPs in 13,738 genes, these
nvestigators found 2 SNPs in lymphotoxin alpha (LTA)
ene exon 3 with a highly significant susceptibility for MI
p  0.00000033, odds ratio 1.8). Furthermore, the LTA
NPs were shown to be proinflammatory by increasing
xpression of vascular cell adhesion molecule and
-selectin. This important and groundbreaking effort
as recently extended by the discovery of a galectin-2
NP, from the galactose-binding lectin family, represent-
ng a critical ligand to LTA (22). Galectin-2, in binding
o LTA, also regulates its secretion. Both macrophages
nd smooth muscle cells in atheroma express LTA and
alectin-2. In over 4,300 patients assessed, an intron-1
NP of galectin-2 was found to be highly significant for
ssociation with MI (p  0.00000026) with the TT allele
onferring protection and the CC allele susceptibility.
his discovery nicely illustrates the extension of a pri-
ary finding in MI genomics. First, identifying the LTA
nchoring effect, then moving on to explore its principal
igand, galectin-2, thereby confirming its pivotal impor-
ance in the genomics of MI. Thus, the acceleration of
nowledge base in the field is well exemplified through
Figure 2. Progress in complex traits. SNP  single nucleotide polymorphism.he previously established biologic pathways.
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Genomics of MI October 18, 2005:1456–65ENOME-WIDE SCANNING AND LINKAGE
he classic approach to determining linkage of a complex
rait has involved the technique of genome-wide scanning
ith microsatellites. This involves selecting approxi-
ately 400 microsatellite markers across the genome that
re evenly spaced every 10 centimorgan (approximately 1
illion bps) (Fig. 4). The goal is to find a locus or
linkage peak” in which there is extensive allele sharing
and with some analyses lack of allele sharing of unaf-
igure 3. (A) The thrombospondin (TSP)-4 mutation. Presence of mRNA
P387)TSP-4 on proliferation of endothelial cells (EC). (C) Effect of TSP-
ells. Cells were plated on plastic preincubated with purified TSP-4 varian
f culture (with permission from Stenina et al. [14]). mut  mutant(P387ected individuals) for the cohort of sibling pairs with a sarticular phenotype. This can be conceived as a simple
frequency distribution” of an allele and that in a general
opulation there would not be any signal or linkage peak
resent. The critical steps in identifying a significant
ocus involve the following: 1) a large population of
amilies (typically 300 with 1,000 affected individu-
ls) with a well characterized and “restrictive” phenotype;
) a logarithm of the odds ratio (LOD) score more than
.5 corresponding to a p  106 (23). The finding of a
protein in endothelial cells, and abnormal calcium binding. (B) Effect of
iants and their fragments on adhesion of human umbilical vein endothelial
0,000 cells/well of 24-well plate), and photographs were taken after 24 h
F  von Willebrand factor; wt  wild type.and
4 var
ts (5ignificant linkage peak translates to having a gene or
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October 18, 2005:1456–65 Genomics of MIenes that are in linkage disequilibrium (close in location)
ith a microsatellite marker. Once the linkage peak is
dentified, the genes in the region can be assessed to
etermine which one(s) is responsible.
This technique has already been successfully applied to
number of complex traits (Table 2). In each case a
ignificant locus was ascertained, and then techniques
uch as fine mapping, positional cloning, or candidate
ene testing were used to identify the specific gene. It is
nteresting to note that while we have seen over 1,600
endelian human traits determined, only about 15
able 1. Some SNPs Validated for Coronary Disease
SNPs Reference
po 4 (OR 1.4–2.0) 10
ymphotoxin  (OR 1.8) 19
X3CR1 (fractalkine) (OR 0.5) 20
BCA1 (OR 0.7–4.2) 21
onnexin-37 (OR 1.4) 18
tromelysin-1 (OR 4.7) 18
AI-1 (OR 1.6) 18
hrombospondin-4 (OR 1.9) 13
BCA1  ABC transporter A1; Apo  apolipoprotein; OR  odds ratio; PAI-1 
lasminogen activator inhibitor; SNPs  single nucleotide polymorphisms.f
igure 4. Schematic of genome with 400 microsatellites evenly spaced for
enome-wide scan markers.omplex traits have been thus far identified for their
enomic basis (24). Accordingly, we are in the early,
ascent phase of complex trait genomics.
A number of genome-wide scans have been performed in
AD and MI (1,25–31). As summarized in Table 3, there
ave been seven such studies in cumulatively more than
,000 families. Each study has found different loci, but the
opulations differed substantially on the basis of sample size,
thnicity, age, and analysis program used to determine
inkage. Furthermore, most used CAD as the phenotype
ather than MI. Thus far, of the seven studies, only one has
etermined the specific gene accounting for a significant
inkage peak.
At Cleveland Clinic, in collaboration with a number of
enters in the U.S., Wang et al. (1) have reported a highly
ignificant linkage peak on chromosome 1p34-36. In 428
ultiplex families, involving 1,613 individuals, with age
f MI at 44 years, several significant loci were identified
y genome-wide scanning (Fig. 5). Of these, the chro-
osome 1 locus was highly significant with a LOD score
f over 11 and genome-wide significance. This LOD
core would correspond to a 1/100 million chance of
nding such a linkage peak in a general, unselected
opulation. There are over 300 genes in this broad locus
panning 32 cM, with significance across four microsat-
llite markers. In the months ahead, it is hoped the
dentity of the specific gene that accounts for this locus
ill be finalized. Of note, we did not find any linkage to
he trait of CAD but found the important evidence of
inkage disequilibrium with the premature MI pheno-
ype.
The DeCode Genetics group (30) in Iceland have been
uccessful in mapping a locus for both MI and stroke to
hromosome 13q12-13 and identifying 5-lipooxygenase
ctivating protein (FLAP) as the gene that accounts for
his linkage peak. This finding has been confirmed in
ritish, Scottish, and, most recently, American cohorts.
he FLAP “gain-of-function” haplotype consists of a
able 2. Progress in Genetics of Complex Traits
Complex Trait Locus Gene(s)
sthma 20p13 ADAM33
2q14 DPP10
7p14–15 GPRA
chizophrenia 6p22–3 Dysbindin-1
lzheimer’s disease 9q22 Ubiquilin-1
troke 5q12 PDE4D
13q12–13 FLAP
BD 10q23 DLG5
rohn’s disease 16q12 CARD15
amilial combined
hyperlipidemia
1q21 USF1
besity 7q22–35 LEP
iabetes (type I) 6q25 SUMO4
ge-related macular
degeneration
1q25 CFH
BD  inflammatory bowel disease.our-SNP marker that is present in approximately 10% of
F

t
P
v
T
P
F
B
H
W
H
H
CAD  coronary artery disease.
1460 Topol JACC Vol. 46, No. 8, 2005
Genomics of MI October 18, 2005:1456–65igure 5. (A) Haseman-Elston sib-pair regression analysis for scanning loci segregating with myocardial infarction. The vertical axis of each plot is
log10(P) or pP, where the P is the significance level from each of two analyses. The solid line denotes the multipoint linkage profile for all pedigrees;
he broken dotted/dashed line denotes the multipoint linkage profile for Caucasian-only pedigrees. The horizontal solid line in each subfigure indicates
5able 3. Seven Genomewide Scans for CAD
Study (Ref.), Year Analysis Programs Population
No. of
Families
Mean Age
(yrs) Locus/Loci
ajukanta et al. (26), 2000 MAPMAKER/SIBS, and SIBPAIR
in the ANALYZER package
Finnish 156 55 2q21 and Xq23
rancke et al. (27), 2001 Genehunter 2.1 Mauritian 99 47 16p13
roeckel et al. (28), 2002 SOLAR European 513 52 14q32
arrap et al. (29), 2002 MAPMAKER/SIBS Australian 61 62 2q36
ang et al. (31), 2004 SAGE American 428 44 1p34–36
auser et al. (25), 2004 Genehunter-Plus Euro-Amer 438 56 3q13
elgadottir et al. (30), 2004 Allegro Icelandic 296 13q12–13 2.2  10 (log10(P)  4.66 or logarithm of the odds ratio score  3.6). The x axis denotes marker map positions. Note that the dashed line (p
alues for Caucasians only) is often not visible because it frequently overlaps with the solid line (p values for all study families). Continued on next page.
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October 18, 2005:1456–65 Genomics of MIndividuals with an MI. It carries a near two-fold risk for
oth MI and stroke. This gene is critical to the transfor-
ation of 5-lipooxygenase (5-LO) to leukotriene B4, one
f the most potent neutrophil cytokines responsible for
nflammation. The 5-LO pathway has been strongly
mplicated for atherosclerosis in transgenic mice, and
an (32,33), and the presence of FLAP and 5-LO is
ndexed to the complexity of the coronary atherosclerotic
esion, with a positive correlation of plaque rupture and
eightened 5-LO/FLAP (34). Recently, the DeCode
nvestigators have performed a randomized trial of a
LAP blocker, conventionally used in patients with
sthma, in over 200 patients with the FLAP gain-of-
unction haplotype. The FLAP inhibitor, compared with
lacebo, led to a significant reduction of neutrophil
eukotriene B4 production and decreased serum
-reactive protein (35). This represents the first gene-
pecific therapeutic program in the field of MI—with a
ersonalized or individualized approach of administering
drug to counter the genetic susceptibility. Its true
alidation will rely on demonstration of clinical outcome
mprovement in patients with the abnormal, at-risk
LAP haplotype, but this may be a harbinger of a new era
f smarter therapeutics that are genomically based in the
uture.
Wang et al. (36) have used a rich pedigree genome-
ide scanning approach to identify the transcription
actor myocyte-enhancing factor 2A (MEF2A) as a cause
f autosomal-dominant inheritance of MI and CAD. In
very large family consisting of 240 living members
ased in Iowa, spanning three generations, the nuclear
igure 5 Continued. (B) Identification of a novel genetic linkage for
yocardial infarction on chromosome 1p34-36. The vertical axis
epresents the log10(P value) or pP, and the horizontal axis denotes
he distance (cM) with markers along the chromosome. The results
ere obtained by multipoint linkage analysis of 2 cM intervals using the
.A.G.E. package (Statistical Analysis for Genetic Epidemiology,
tatistical Solutions, Cork, Ireland). The asymptotic p values were
uoted accurately to only 12 decimal places, resulting in a flat pP peak
with permission from Wang et al. [1]).amily of 21 members were initially assessed with penome-wide scanning. A specific haplotype on chromo-
ome 15 near its telomere co-segregated in the family
Fig. 6), meaning that it was found in all affected, and not
ound in those unaffected. In this region of over 60 genes,
EF2A was considered a candidate because of its known
ffect in the development of heart muscle, albeit without
nowledge of coronary arterial impact. In assessing the
roband’s sequence of MEF2A, a 21 bp deletion was
ound in exon 11, the stop codon or last coding sequence
f this gene. The same 21 bp deletion was identified in all
embers of the family affected, and not present in family
embers unaffected of 200 controls from our large
enetic repository of individuals who have undergone
oronary angiography. The functional genomics of this
eletion mutation, leading to a seven amino-acid “in
rame” truncation, were carried out to show the inability
or this transcription factor to localize in the nucleus, the
resence of MEF2A in the endothelial layer of the artery,
nd the shutdown of transcription using a standard assay
echnique. Further work is necessary to account more
recisely for the specific pathogenesis of MI with an
EF2A deletion.
The work on MEF2A was recently extended by the
iscovery that mutations in this gene may account for MIs
eyond the original family with an autosomal-dominant
nheritance pattern. In over 400 MI cases and controls,
EF2A mutations were found in 1.9% of cases and no
ontrols (37). Rather than involving exon 11, the mutations
ere point ones leading to a change of amino acids from
xon 7. These point mutations (Fig. 7) also were responsible
or significant limitation of transcription activity of
EF2A. This extension of MEF2A significance from a
ingle family to the broader population demonstrates the
alue of such a rich pedigree approach in identifying novel
I genes.
Recently, Weng et al. (38) published findings challeng-
ng the MEF2A association with MI. These investigators
ound individuals with the same exon 11 21 bp deletion
ho did not have CAD (38). Furthermore, a missense
EF2A mutation (S360L), found only in a patient with
AD, was deemed benign using computational analysis
38). An accompanying editorial by Altshuler and
irschhorn (39) claimed that the “genetic evidence
vailable to date does not demonstrate that these muta-
ions play a causal role in CAD and/or MI in humans.”
ur group responded to the concern about lack of
eplication, pointing out that the S360L missense muta-
ion, in the critical transcriptional activation domain, may
ell be a disease-causing variant (40). The lack of
oronary disease among the four individuals with the 21
p deletion may well have been accounted for by inade-
uate phenotyping. These patients did not undergo
oronary angiography, and one proband had a transient
schemic attack suggesting cerebrovascular disease. The
ossibility of incomplete penetrance was raised (38,40).
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Genomics of MI October 18, 2005:1456–65ince these reports, a new study from a Spanish team of
nvestigators has confirmed marked susceptibility for
AD with a missense MEF2A mutation in a large cohort
f over 1,500 cases and controls (41). Clearly, more
nvestigation will be required to determine the precise
elationship of MEF2A variants and CAD. Notwith-
tanding these concerns, the proof for MEF2A as a
isease-causing gene stems from its co-segregation in a
arge family, functional data demonstrating the deleteri-
us effect on the function of the MEF2A protein,
dentification of multiple missense mutations in other
atients and families, and replication by independent
igure 6. (A) Genetic linkage of coronary artery disease (CAD)/myocardia
nalysis of kindred QW1576. Individuals with CAD are indicated by close
y open symbols. Normal men under the age of 50 years or normal wom
eceased individuals are indicated by a slash, “/.” The proband is indicated b
re shown below each symbol. Initial linage was identified with D15S120
raction of 0. Haplotype cosegregating with the disease is indicated by a b
he 21-base pair (bp) deletion allele (21bp) of MEF2A. Sequence analysis
he WT and deletion alleles were separated by a 3% agarose gel and a s
irectly. The location of 21bp is indicated. Continued on next page.nvestigators. rENOME-WIDE SNP ASSOCIATION
n exciting advance in the field has been made by Hinds et
l. (42) from Perlegen Science with the genotyping of
,586,383 SNPs in 71 individuals of diverse ethnic and
acial origin. This is the most extensive and informative
enotyping that has ever been accomplished beyond the
nitial complete sequence of a couple of individuals. It has
lready provided critical insight into human genomic vari-
tion, with the demonstration of approximately 30% “pri-
ate” SNPs relegated to a particular ethnicity or race (Asian,
frican, or European-American) and 70% “cosmopolitan”
rction to chromosome 15q26 (adCAD1). Pedigree structure and genotypic
ares (men) or closed circles (women). Unaffected individuals are indicated
s than 55 years are shown with light gray color as uncertain phenotype.
rrow. Genotypes for markers D15S104, D15S212, D15S120, and D15S87
h yielded a logarithm of the odds ratio score of 4.19 at a recombination
ertical bar. (B) DNA sequence analysis of the wild-type (WT) allele and
n 11 of MEF2A in the proband (II.1) revealed the presence of a deletion.
strand conformation polymorphism (SSCP) gel, purified and sequencedl infa
d squ
en les
y an a
, whic
lack v
of exo
ingle-eferring to sharing of the SNPs across the diverse popula-
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October 18, 2005:1456–65 Genomics of MIions. Along with this breakthrough, the International
aplotype Map (known as HapMap) (43) is proceeding
o unravel nearly three million SNPs in 270 individuals or
pproximately one SNP per 1,000 bases across the
enome (44). This will get us substantially closer to a
ully informative set of approximately 500,000 haplotype-
ag SNPs. Such SNPs are the index or window to a
aplotype block, providing considerable information be-
ond an SNP that is not identifying a much more
xtensive pattern or block in the genome. These major
dvances will undoubtedly facilitate the objectives of
etermining MI genes in the future. Rather than finding
locus with microsatellites, the whole genome SNP
ssociation will permit the actual identity of SNPs and
aplotypes that are associated with MI. Eventually, the
bility to sequence the entire genome of individuals may
ven further accelerate the identity of key genes that
etermine susceptibility for MI. The implications of this
apid and revolutionary jump in high throughput geno-
yping comes at a time when complex trait validation has
ained considerable momentum and the initial genes that
re linked to MI have begun to be unraveled. As opposed
o long QT syndrome and hypertrophic cardiomyopathy,
n which more than 75% of the genes for these Mendelian
raits have been characterized, we are clearly at a much
ess formative point with 10% of MI genes having been
igure 6 Continued. (C) 21bp results in a deletion of seven amino ac
haracterization of WT and 7aa MEF2A proteins by transcriptional activ
as analyzed in the presence or absence of the zinc-finger transcription fa
s relative luciferase activity on the y axis. The transcriptional activity of th
ntiMEF2A rabbit polyclonal antiserum showed that both WT and mutan
n the box; C, vector only as negative control; the MEF2A antibody detecte
xperiments in triplicate, and are expressed as mean  S.E. WT  wild ty
7aa  the 7 amino acid deletion of MEF2A. (With permission from Whus far determined. tMPLICATIONS FOR THE FUTURE
ack in 1985, Brown and Goldstein were awarded the
obel Prize for their discovery of an autosomal-
ominant inheritance of the low-density lipoprotein re-
eptor accounting for familial hypercholesterolemia, and
eading to the discovery of statins. In 1996, these inves-
igators published a controversial editorial in Science
ntitled “Heart Attacks: Gone With the Century? (45).
hey wrote “. . . better definition of genetic susceptibility
actors—may well end coronary disease as a major public
ealth problem early in the next century.” It appears
nlikely that we will be rid of CAD in the imminent years
head, owing not only to its pervasiveness but the
ngoing diabesity epidemic. On the other hand, MI is
uch more heritable and appears to be a more ideal,
estrictive phenotype as a complex trait that is making it
n attractive discovery target for determination of its
enetic basis. If most individuals who carry MI-
usceptible genes can be recognized at an early age,
revention, lifestyle factors, and personalized drug ap-
roaches could be implemented to markedly reduce the
oll of MI in the future. Indeed, it does seem possible that
hrough genomic definition of MI we will see a time in
he years ahead that MI is an unusual event albeit not
gone with the century.” Yet, limiting the MI events has
f MEF2A (Q 440P441P442Q 443P444Q 445P446 or 7aa). (D) Functional
assays. The effect of 7aa on transcription activation activity of MEF2A
ATA-1 using the ANF700 promoter. Transcriptional activity is shown
rter gene only (vector) was set arbitrarily to 1. Western blot analysis with
F2A (7aa) were successfully expressed in transfected HeLa cells (shown
bands as previously reported). The data shown were from two independent
F2A; WT/7aa  coexpression of both wild type and mutant MEF2As;
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dvances in the next decade. Undoubtedly, a not-so-
istant future Simon Dack lecture will be dedicated to
he overwhelming triumph of reduction in the incidence
nd toll of MI.
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